Caris Life Sciences - About the company
Caris Life Sciences is a public company based in Irving (United States), founded in 1996. It operates as a Developer of panomic disease profiling technologies for cancer precision medicine. Caris Life Sciences has raised $1.23B in funding from investors like Coatue, Highland Capital Management and Sixth Street. The company has 743 active competitors, including 225 funded and 163 that have exited. Its top competitors include companies like Natera, Guardant Health and MedGenome.
Sectors and market segments that Caris Life Sciences operate in
Caris Life Sciences serves in the Life Sciences market segments.The primary business model of Caris Life Sciences are:Company Details
Developer of panomic disease profiling technologies for cancer precision medicine. The company leverages artificial intelligence (AI) and machine learning algorithms. Leveraging our proprietary AI analytics engine, DEAN for advancing the oncology precision medicine platform. It offers tumor profiling services, a complete molecular blueprint, and guiding personalized cancer treatment.
- Website
- www.carislifesciences.com/
- Social
- Registered Address
- Irving, Texas
Key Metrics
Founded Year
1996
Location
Irving, United States
Stage
Public
Total Funding
$1.23B in 9 rounds
Latest Funding Round
Ranked
11th among 743 active competitors
Annual Revenue
$500M - $1B as on Dec 31, 2025
Employee Count
61 as on Sep 30, 2026
Investment & Acquisitions
Exit Details
Public
Legal entities associated with Caris Life Sciences
Caris Life Sciences is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CARIS LIFE SCIENCES, INC. CIN: 2019410 , United States, Active | $500M - $1B (As on Dec 31, 2025) | - | - | |
CARIS SCIENCE INC. CIN: 453632909 , United States, Active | Dec 26, 999 | - | 1760 (As on Dec 31, 2024) | - |
MIRACA LIFE SCIENCES, INC. CIN: 621637129 , United States, Active | Dec 31, 1999 | - | 504 (As on Dec 31, 2022) | - |
Caris Life Sciences's IPO details
Caris Life Sciences got listed on Jun 18, 2025.
Click here to take a look at Caris Life Sciences's IPO in detail
Sign up to download Caris Life Sciences' company profile
Caris Life Sciences's funding and investors
Caris Life Sciences has raised a total funding of $1.23B over 9 rounds. Its first funding round was on Jan 09, 2017. Its latest funding round was a Series D round on Apr 07, 2025 for $168M. 6 investors participated in its latest round. Caris Life Sciences has 21 institutional investors.
Here is the list of recent funding rounds of Caris Life Sciences:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 07, 2025 | $168M | Series D | - | - | ||
Jan 19, 2023 | Undisclosed | Conventional Debt | - | - | - | |
May 11, 2021 | $830M | Series D | $7.83B | - |
Access funding benchmarks and valuations. Sign up today!View details of Caris Life Sciences's funding rounds and investors
Caris Life Sciences' founders and board of directors
Founder? Claim ProfileCaris Life Sciences' employee count trend
Caris Life Sciences has 61 employees as of Sep 26. Here is Caris Life Sciences's employee count trend over the years:
Uncover Caris Life Sciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Caris Life Sciences's Competitors and alternates
Top competitors of Caris Life Sciences include Natera, Guardant Health and MedGenome. Here is the list of Top 10 competitors of Caris Life Sciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
2nd |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 75/100 | |
3rd | Provider of DNA sequencing, bioinformatics, and multiomics services | $264M | 70/100 | ||
4th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 70/100 | |
5th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 69/100 | ||
6th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
7th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 68/100 | |
8th | Geneoscopy 2015, St. Louis (United States), Series C | Developer of non-invasive biomarker tests for colorectal cancer | $219M | 67/100 | |
9th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases | $85M | 66/100 | |
10th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
11th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 67/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Caris Life Sciences's competitors? Click here to see the top ones
Caris Life Sciences's Investments and acquisitions
Caris Life Sciences has acquired Pharmatech. Caris Life Sciences has not made any investments as of now.Reports related to Caris Life Sciences
Here is the latest report on Caris Life Sciences's sector:
News related to Caris Life Sciences
Filter this listMedia has covered Caris Life Sciences for a total of 17 events in the last 1 year, 14 of them have been about company updates.
•
Edmond DE Rothschild Holding S.A. Buys Shares of 27,965 Caris Life Sciences, Inc. $CAIThecerbatgem•Aug 21, 2026•Edmond de Rothschild, Caris Life Sciences
•
Perigon Wealth Management LLC Invests $438,000 in Caris Life Sciences, Inc. $CAIThecerbatgem•Aug 21, 2026•Perigon Wealth Management, Caris Life Sciences
•
Handelsbanken Fonder AB Buys Shares of 36,300 Caris Life Sciences, Inc. $CAIAmerican Banking News•Aug 21, 2026•Handelsbanken, Caris Life Sciences
•
Meeder Asset Management Inc. Takes Position in Caris Life Sciences, Inc. $CAIAug 19, 2026•Meeder Investment Management, Caris Life Sciences
•
Caris forecasts $1.03B-$1.04B 2026 revenue as it scales Detect capacity toward $3B run rate (NASDAQ:CAI)Seeking Alpha•Aug 06, 2026•Caris Life Sciences
•
Caris Life Sciences Offers In-House PTEN Immunohistochemistry Testing for Metastatic Prostate CancerStock Screener•Jul 14, 2026•Caris Life Sciences
•
Caris Life Sciences (NASDAQ:CAI) Director Jon Halbert Buys 68,000 Shares of StockTranscript Daily•Jul 13, 2026•Caris Life Sciences
•
Caris Life Sciences (NASDAQ:CAI) Given Buy Rating at BTIG ResearchWatch List News•Jul 02, 2026•Caris Life Sciences
•
•
Caris Life Sciences authorizes $100M share buyback programSeeking Alpha•Jun 08, 2026•Caris Life Sciences
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Caris Life Sciences
Explore our recently published companies
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company
